FindTrial
Sign In

PROPHYLACTIC ANTIBIOTIC TREATMENT IN END-STAGE KIDNEY DISEASE AND CENTRAL VENOUS CATHETER AS HEMODIALYSIS VASCULAR ACCESS

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515001-26-00
Acronym
12020
Enrollment
800
Registered
2024-07-25
Start date
2024-07-25
Completion date
Unknown
Last updated
2024-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood poisoning in patients with renal failure treated with hemodialysis

Brief summary

Hospitalization for BSI ≤ 6 months after randomization, Hospitalization ≥ 3 days due to infection defined as: CRP ≥ 75 and negative blood cultures, treated with iv antibiotics, and occurring ≤ 6 months after randomization

Interventions

DRUGClindamycin ”Alternova”
DRUGhårde kapsler
DRUGAmoxicillin/clavulansyre ”Aurobindo”
DRUGfilmovertrukne tabletter

Sponsors

Region Sjaelland
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Hospitalization for BSI ≤ 6 months after randomization, Hospitalization ≥ 3 days due to infection defined as: CRP ≥ 75 and negative blood cultures, treated with iv antibiotics, and occurring ≤ 6 months after randomization—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026